drugset / Trial / NCT02794077
Cyclophosphamide for Nasopharyngeal Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
There is no standard third-line systemic treatment for inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma (NPC). We investigated the efficacy and safety of metronomic oral cyclophosphamide as third-line treatment or beyond.
Timeline
- Start
- 2008-01
- Primary completion
- 2015-12
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 50 mg | Oral |
| Subject | Cyclophosphamide | Other / unclassified | 150 mg | Oral |